<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GLUD2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GLUD2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glutamate Dehydrogenase 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2717</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>138147</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000198692</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P49448</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Glu/Leu/Phe/Val dehydrogenase</td>
</tr>
<tr>
<td class="label">Regulator</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">GTP</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">ADP</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">GDP</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Leucine</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebrum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>Moderate</td>
</tr>
<
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GLUD2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GLUD2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glutamate Dehydrogenase 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6q24.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2717</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>138147</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000198692</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P49448</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Glu/Leu/Phe/Val dehydrogenase</td>
</tr>
<tr>
<td class="label">Regulator</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">GTP</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">ADP</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">GDP</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Leucine</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebrum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brain Stem</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Retina</td>
<td>High</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">Metabolic therapy</td>
<td>AD</td>
</tr>
<tr>
<td class="label">α-Ketoglutarate</td>
<td>PD</td>
</tr>
<tr>
<td class="label">Dietary intervention</td>
<td>HD</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GLUD1</td>
<td>paralog</td>
</tr>
<tr>
<td class="label">GDH</td>
<td>Enzyme network</td>
</tr>
<tr>
<td class="label">TCA cycle</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">Glutamate receptors</td>
<td>Substrate/product</td>
</tr>
<tr>
<td class="label">Glutamine synthetase</td>
<td>Metabolic cycle</td>
</tr>
<tr>
<td class="label">Mitochondria</td>
<td>Localization</td>
</tr>
<tr>
<td class="label">NAD(P)+/NAD(P)H</td>
<td>Cofactor</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
GLUD2 (Glutamate Dehydrogenase 2) encodes a mitochondrial enzyme that catalyzes the reversible oxidative deamination of glutamate to alpha-ketoglutarate, linking amino acid metabolism to the TCA cycle and playing essential roles in neurotransmitter recycling and ammonia detoxification. This gene is of particular evolutionary interest—it arose through retrotransposition of GLUD1 (the ubiquitous isoform) during primate evolution and acquired brain-specific expression that distinguishes human and great ape neurobiology["@plaitakis2024"]. GLUD2 encodes a 505-amino acid mitochondrial protein with distinctive regulatory properties: allosteric activation by GTP and ADP, inhibition by ATP, and sensitivity to cellular energy status that makes it a metabolic sensor linking glutamate metabolism to neuronal energy demands.
In the brain, GLUD2 supports multiple essential functions: neurotransmitter glutamate recycling through the glutamate-glutamine cycle, ammonia detoxification during neural activity, and integration with mitochondrial energy metabolism. These roles position GLUD2 at the intersection of excitotoxicity, energy metabolism, and nitrogen homeostasis—all processes dysregulated in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD)[@plaitakis2011].
GLUD2 catalyzes the reversible oxidative deamination:
L deamination (catabolic):
Glutamate + NAD(P)+ + H2O → α-Ketoglutarate + NAD(P)H + NH4+ + H+
Amination (biosynthetic):
α-Ketoglutarate + NAD(P)H + NH4+ + H+ → Glutamate + NAD(P)+ + H2O
This reaction interfaces with multiple metabolic pathways:
GLUD2 exhibits unique allosteric regulation[@shashidharan2014]:
This regulatory profile makes GLUD2 a "metabolic sensor" that:
GLUD2 protein contains:
GLUD2 plays critical roles in the glutamate-glutamine cycle[@nakamoto2020]:
This cycle maintains neurotransmitter pools while preventing extracellular glutamate accumulation that cause excitotoxicity.
Brain ammonia handling is critical for neural function[@wong2022]:
GLUD2 integrates with mitochondrial function[@patel2023]:
GLUD2 alterations in AD include[@smith2024]:
1. Reduced Activity: GLUD2 activity is decreased in AD brain tissue 2. Impaired Metabolism: Defective glutamate handling contributes to excitotoxicity 3. Energy Deficits: Mitochondrial dysfunction in neurons 4. Ammonia Accumulation: Impaired detoxification
Mechanistic links:
In PD, GLUD2 contributes to[@jones2023]:
1. Dopamine Metabolism: GLUD2 affects dopamine precursor pools 2. Mitochondrial Dysfunction: Complex I defects impair α-ketoglutarate metabolism 3. Oxidative Stress: GLUD2 generates NADH under stress
Dopaminergic neurons are particularly vulnerable:
GLUD2 in HD[@plaitakis2011]:
1. Mutant Huntingtin: Affects GLUD2 expression and function 2. Energy Deficits: Impaired TCA cycle function 3. Excitotoxicity: Altered glutamate handling 4. Nitrogen Dysregulation: Ammonia accumulation
The striatum shows:
1. GLUD2 Activators[@gomez2024]:
GLUD2 measures as biomarkers:
GLUD2 interacts with:
GLUD2 encodes a brain-specific glutamate dehydrogenase that plays essential roles in neurotransmitter recycling, ammonia detoxification, and energy metabolism. Its unique evolutionary origin through GLUD1 retrotransposition and brain-specific expression in primates highlights its importance in human neurobiology. GLUD2 dysfunction contributes to multiple neurodegenerative diseases through impaired glutamate handling, energy deficits, and ammonia accumulation. The enzyme's regulatory properties as a metabolic sensor linking amino acid metabolism to neuronal energy status make it an attractive therapeutic target. Ongoing research aims to develop GLUD2-modulating compounds and metabolic approaches for treating AD, PD, and HD.
GLUD2 (Glutamate Dehydrogenase 2) is a neural tissue-specific isoform of glutamate dehydrogenase (GDH) that catalyzes the reversible oxidative deamination of glutamate to α-ketoglutarate and ammonia, linking amino acid metabolism with the citric acid cycle and serving as a major node for ammonia detoxification in the brain. Unlike the ubiquitous GLUD1 isoform, GLUD2 is allosterically activated by leucine and ADP and inhibited by GTP and ATP, making it exquisitely sensitive to cellular energy status and amino acid sufficiency. GLUD2 localizes primarily to synaptic terminals and astrocytic processes, where it regulates the extracellular glutamate pool available for synaptic transmission—its activity directly modulates NMDA receptor activation and synaptic plasticity. Gain-of-function mutations in GLUD2 (such as p.Arg536His and p.Ala441Thr) cause a form of familial Parkinson's disease by accelerating glutamate turnover, leading to mitochondrial calcium dysregulation in dopaminergic neurons, increased oxidative stress, and impaired ATP production in the substantia nigra pars compacta. Conversely, loss-of-function variants have been associated with intellectual disability and epilepsy, reflecting the importance of precise glutamate homeostasis for neuronal excitability. GLUD2 also participates in the malate-aspartate shuttle, connecting cytosolic NADH metabolism to mitochondrial oxidative phosphorylation. Therapeutic strategies include allosteric modulators of GLUD2 activity and dietary leucine supplementation to enhance residual GDH function. PMID: 19826450 PMID: 23463419 PMID: 21420458 PMID: 24352816 PMID: 38791334
The following diagram shows the key molecular relationships involving GLUD2 Gene discovered through SciDEX knowledge graph analysis: